Novartis Piqray® – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval[1]
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase ...